JT:4536 Santen Pharmaceutical Co., Ltd

Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. It offers prescription pharmaceutical products for glaucoma and ocular hypertension, dry eyes, allergic conjunctivitis, severe keratitis with dry eyes, vernal keratoconjunctivitis, uveitis, wet age-related macular degeneration, and myopia; and over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.This company has ADRs that trade in the U.S. as the symbol SNPHY.

1,112.00 JPY
As of 03/24/2023

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-General
Index country:  Japan
Country of incorporation:  Japan
IPO date:  01/12/1984
Stock exchange:    Tokyo Stock Exchange
Exchange country:   Japan
Market cap:   402,945,998,848 JPY
Current dividend yield:   3.14%
Sedol:      6776606